Endothelial SOCS3 maintains homeostasis and promotes survival in endotoxemic mice

SOCS3 is the main inhibitor of the JAK/STAT3 pathway. This pathway is activated by interleukin 6 (IL-6), a major mediator of the cytokine storm during shock. To determine its role in the vascular response to shock, we challenged mice lacking SOCS3 in the adult endothelium (SOCS3(IEKO)) with a nonlethal dose of lipopolysaccharide (LPS). SOCS3(IEKO) mice died 16-24 hours postinjection after severe kidney failure. Loss of SOCS3 led to an LPS-induced type I IFN-like program and high expression of prothrombotic and proadhesive genes. Consistently, we observed intraluminal leukocyte adhesion and neutrophil extracellular trap-osis (NETosis), as well as retinal venular leukoembolization. Notably, heterozygous mice displayed an intermediate phenotype, suggesting a gene dose effect. In vitro studies were performed to study the role of SOCS3 protein levels in the regulation of the inflammatory response. In human umbilical vein endothelial cells, pulse-chase experiments showed that SOCS3 protein had a half-life less than 20 minutes. Inhibition of SOCS3 ubiquitination and proteasomal degradation led to protein accumulation and a stronger inhibition of IL-6 signaling and barrier function loss. Together, our data demonstrate that the regulation of SOCS3 protein levels is critical to inhibit IL-6-mediated endotheliopathy during shock and provide a promising therapeutic avenue to prevent multiorgan dysfunction through stabilization of endothelial SOCS3.

Automated summary

Studies have shown that lack of SOCS3 protein in mice leads to severe kidney failure and death after shock, with associated changes including increased expression of prothrombotic and proadhesive genes and formation of neutrophil extracellular traps. It has been demonstrated that regulating SOCS3 protein levels is critical for inhibiting IL-6-mediated endotheliopathy during shock and may provide a promising therapeutic avenue for preventing multiorgan dysfunction.